Furthermore, a great deal of attention has been attracted by a serial of studies that inhibition of PDE4 could be a promising therapeutic strategy for IBD, including improvement of intestinal barrier function, intestinal fibrosis, inflammation, and the composition of gut microbiota [7–11]. The gene discussed is PDE4A; the disease is inflammatory bowel disease.